Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

INOVIO PHARMACEUTICAL INC (GBMB.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
1.7170+0.1256 (+7.89%)
At close: 09:01PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5914
Open1.5928
Bid1.7552 x N/A
Ask1.7928 x N/A
Day's Range1.5836 - 1.7646
52 Week Range1.2960 - 3.5925
Volume17
Avg. Volume8
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Inovio Pharma Releases Favorable Data From Booster DNA Vaccine Candidate For Ebola

    Inovio Pharmaceuticals Inc (NASDAQ: INO) announced results from a Phase 1b trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo. Ervebo is an FDA-approved vaccine to prevent ebola in individuals 18 years and older. In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. Dr. Laurent Humeau, PhD, INOVIO's Chief Scientific Officer, said, "We are

  • American City Business Journals

    Inovio Pharmaceuticals enacts its second round of layoffs in just over six months

    The company also announced court approval of a previously disclosed $44 million settlement to resolve a class-action shareholder lawsuit.

  • Benzinga

    INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates

    INOVIO Pharmaceuticals (NASDAQ: INO) announced a strategic reorganization expected to provide annual savings of approximately $4.3 million and includes an 11% reduction of full-time employees following the previously announced discontinuation of clinical development programs in late 2022. In October, the company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. These and other strategic measures redirect resources to advance key programs,

Advertisement
Advertisement